MiR-34 - a microRNA replacement therapy is headed to the clinic

Frontiers in Genetics

Volumn 3, Issue JUL, 2012, Pages

  Bader, Andreas G ^a  

^a SYNLOGIC   (United States)

Author keywords

Mir 34; Mir 34a; MiRNA; MiRNA replacement; MiRNA therapeutics

Indexed keywords

ANIMALIA;

EID: 84869219338     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00120     Document Type: Article

References (83)

1. Akao, Y., Noguchi, S., Iio, A., Kojima, K., Takagi, T., and Naoe, T. (2010). Dys-regulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 300,197-204.
2. Asslaber, D., Pinon, J. D., Seyfried, I., Desch, P., Stocher, M., Tinhofer, I., Egle, A., Merkel, O., and Greil, R. (2010). microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 115,4191-4197.
3. Bader,A. G., Brown, D., andWinkler, M. (2010). The promise of microRNA replacement therapy. Cancer Res. 70, 7027-7030.
4. Bader, A. G., Daige, C. L., Kelnar, K., Priddy, L., Dysart, S., Wiggins, J., Zhao, J., Leatherbury, N., Omotola, M., Stoudemire, J., Lammers, P., and Brown, D. (2012). Preclinical data of a microRNA-based therapy for hepatocellular carcinoma. Annual AACR Conference Presentation, March 31- April 4, 2012, Chicago, IL.
5. Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., MacDougald, O. A., Cho, K. R., and Fearon, E. R. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17, 1298-1307.
6. Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., and Croce, C. M. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 101, 2999-3004.
7. Catalogue of Somatic Mutations in Cancer. Wellcome Sanger Trust Institute, WSAU. Available at: http://www.sanger.ac.uk
8. Chang, T. C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., Arking, D. E., Beer, M. A., Maitra, A., and Mendell, J. T. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell26, 745-752.
9. Chen, Q. R., Yu, L. R., Tsang, P., Wei, J. S., Song, Y. K., Cheuk, A., Chung, J. Y., Hewitt, S. M., Veenstra, T. D., and Khan, J. (2010). Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a.J. Proteome Res. 10, 479-487.
10. Chen, X., Hu, H., Guan, X., Xiong, G., Wang, Y., Wang, K., Li, J., Xu, X., Yang, K., and Bai, Y (2011). CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int. J. Cancer 130, 1607-1613.
11. Chen, Y., Zhu, X., Zhang, X., Liu, B., and Huang, L. (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18, 1650-1656.
12. Chim, C. S., Wong, K. Y., Qi, Y., Loong, E, Lam, W. L., Wong, L. G., Jin, D. Y., Costello, J. F., and Liang, R. (2010). Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31, 745-750.
13. Choi, Y. J., Lin, C. P., Ho, J. J., He, X., Okada, N., Bu, P., Zhong, Y., Kim, S. Y., Bennett, M. J., Chen, C., Ozturk, A., Hicks, G. G., Hannon, G. J., and He, L. (2011). miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat. Cell Biol. 13, 1353-1360.
14. Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., and Lund, A. H. (2009). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 17,236-245.
15. Cole, K. A., Attiyeh, E. F., Mosse, Y P., Laquaglia, M. J., Diskin, S. J., Brodeur, G. M., and Maris, J. M. (2008). A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 6, 735-742.
16. Corney, D. C., Hwang, C. I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., and Nikitin, A. Y (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16,1119-1128.
17. Craig, V. J., Cogliatti, S. B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H., Schlapbach, R., Dirnhofer, S., Tzankov, A., and Muller, A. (2011). Mycmediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 117, 6227-6236.
18. Craig, V. J., Tzankov, A., Flori, M., Schmid, C. A., Bader, A. G., and Muller, A. (2012). Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. doi: 10.1038/leu.2012.110 [Epub ahead of print].
19. Daige, C., Priddy, L., Kelnar, K., Zhao, J., Dysart, S., Bader, A., and Brown, D. (2011). The development of a miRNA-based therapeutic candidate for hepatocellular carcinoma. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, November 12-16, 2011, San Francisco, CA. Abstract no. C142.
20. de Antonellis, P., Medaglia, C., Cusanelli, E., Andolfo, I., Liguori, L., De Vita, G., Carotenuto, M., Bello, A., Formiggini, F., Galeone, A., De Rosa, G., Virgilio, A., Scognamiglio, I., Sciro, M., Basso, G., Schulte, J. H., Cinalli, G., Iolascon, A., and Zollo, M. (2011). MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS ONE 6, e24584. doi: 10.1371/journal. pone.0024584
21. Du, R., Sun, W., Xia, L., Zhao, A., Yu, Y., Zhao, L., Wang, H., Huang, C., and Sun, S. (2012). Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS ONE 7, e30771. doi: 10.1371/journal.pone.0030771
22. Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J. B., Brown, D., Bader, A. G., and Slack, F. J. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7, 759-764.
23. Feinberg-Gorenshtein, G., Avigad, S., Jeison, M., Halevy-Berco, G., Mardoukh, J., Luria, D., Ash, S., Steinberg, R., Weizman, A., and Yaniv, I. (2009). Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site. Genes Chromosomes Cancer 48, 539-543.
24. Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., Deguchi, T., and Ito, M. (2008). Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 377, 114-119.
25. Gallardo, E., Navarro, A., Vinolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., and Monzo, M. (2009). miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30, 1903-1909.
26. Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N. Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C. R., Nohadani, M., Eklund, A. C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P. A., and Swanton, C. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892.
27. Greenberg, E., Hershkovitz, L., Itzhaki, O., Hajdu, S., Nemlich, Y., Ortenberg, R., Gefen, N., Edry, L., Modai, S., Keisari, Y., Besser, M. J., Schachter, J., Shomron, N., and Markel, G. (2011). Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS ONE 6, e18936. doi: 10.1371/journal.pone.00 18936
28. Hashimi, S. T., Fulcher, J. A., Chang, M. H., Gov, L., Wang, S., and Lee, B. (2009). MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood 114, 404-414.
29. He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., Jackson, A. L., Linsley, P. S., Chen, C., Lowe, S. W., Cleary, M. A., and Hannon, G. J. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134.
30. Hsu, S. D., Chu, C. H., Tsou, A. P., Chen, S. J., Chen, H. C., Hsu, P. W., Wong, Y H., Chen, Y H., Chen, G. H., and Huang, H. D. (2008). miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 36,D165-D169.
31. Ichimura, A., Ruike, Y., Terasawa, K., Shimizu, K., and Tsujimoto, G. (2010). MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol. Pharmacol. 77, 1016-1024.
32. Ji, Q., Hao, X., Meng, Y., Zhang, M., Desano, J., Fan, D., and Xu, L. (2008). Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumor-spheres. BMC Cancer 8, 266. doi: 10.1186/1471-2407-8-266
33. Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., Desano, J. T., Bommer, G. T., Fan, D., Fearon, E. R., Lawrence, T. S., and Xu, L. (2009). MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4, e6816. doi: 10.1371/journal. pone.0006816
34. Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., and Slack, F. J. (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635-647.
35. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S. M., Fu, B., Lin, M. T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., and Kinzler, K. W. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
36. Kaller, M., Liffers, S. T., Oeljeklaus, S., Kuhlmann, K., Roh, S., Hoffmann, R., Warscheid, B., and Hermeking, H. (2011). Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol. Cell. Pro-teomics 10, M111.010462.
37. Kim, H. R., Roe, J. S., Lee, J. E., Hwang, I. Y., Cho, E. J., and Youn, H. D. (2012). A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. Biochem. Biophys. Res. Commun. 418, 682-688.
38. Kim, N. H., Kim, H. S., Kim, N. G., Lee, I., Choi, H. S., Li, X. Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., Park, C., Kim, K., Lee, S., Gumbiner, B. M., Yook, J. I., and Weiss, S. J. (2011). p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal. 4, ra71.
39. Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., and Ito, M. (2010). MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70, 1501-1512.
40. Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C L., Hwang, H. W., Chang, T. C., Vivekanandan, P., Torbenson, M., Clark, K. R., Mendell, J. R., and Mendell, J. T. (2009). Thera peutic microRNA delivery suppresses tumorigenesis in a murine liver can cer model. Cell 137, 1005-1017.
41. Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., and Jacks, T. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U.S.A. 105,3903-3908.
42. Kuo, K. T., Guan, B., Feng, Y., Mao, T. L., Chen, X., Jinawath, N., Wang, Y., Kurman, R. J., Shih Ie, M., and Wang, T. L. (2009). Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 69,4036-4042.
43. Li, B., Hu, Y., Ye, F., Li, Y., Lv, W., andXie,X. (2010). Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int. J. Gynecol. Cancer 20, 597-604.
44. Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., and Zheng, X. (2009). miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275, 44-53.
45. Li, W. B., Ma, M. W., Dong, L. J., Wang, E, Chen, L. X., and Li, X. R. (2011). MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblas-toma multiforme. Cancer Biol. Ther. 12,477-483.
46. Li, W Q., Chen, C., Xu, M. D., Guo, J., Li, Y M., Xia, Q. M., Liu, H. M., He, J., Yu, H. Y., and Zhu, L. (2011). The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J. 278, 1522-1532.
47. Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., Wiggins, J. F., Bader, A. G., Fagin, R., Brown, D., and Tang, D. G. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.Nat. Med. 17,211-215.
48. Liu, X., Sempere, L. F., Ouyang, H., Memoli, V. A., Andrew, A. S., Luo, Y., Demidenko, E., Korc, M., Shi, W., Preis, M., Dragnev, K. H., Li, H., Direnzo, J., Bak, M., Freemantle, S. J., Kauppinen, S., and Dmitrovsky, E. (2010). MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.J. Clin. Invest. 120,1298-1309.
49. Lize, M., Pilarski, S., and Dobbel-stein, M. (2009). E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 17,452-458.
50. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Korner, H., Knyazev, P., Diebold, J., and Hermeking, H. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7,2591-2600.
51. Luan, S., Sun, L., and Huang, F. (2010). MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch. Med. Res. 41, 67-74.
52. Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sanchez-Cespedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., Gallagher, W M., Eccles, S. A., Croce, C. M., and Esteller, M. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U.S.A. 105, 13556-13561.
53. Maes, O. C., Sarojini, H., and Wang, E. (2009). Stepwise up-regulation of microRNA expression levels from replicating to reversible and irreversible growth arrest states in WI-38 human fibroblasts. J. Cell. Physiol. 221, 109-119.
54. Mirna Therapeutics, Inc. (2011). Marina Biotech and Mirna Therapeutics announce license agreement for the development of microRNA-based therapeutics. Available at: www.mirnarx.com.
55. Mraz, M., Malinova, K., Kotaskova, J., Pavlova, S., Tichy, B., Malcikova, J., Stano Kozubik, K., Smardova, J., Brychtova, Y., Doubek, M., Trbusek, M., Mayer, J., and Pospisilova, S. (2009). miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia23, 1159-1163.
56. Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., and Allgayer, H. (2011). Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30, 2888-2899.
57. Navarro, F., Gutman, D., Meire, E., Caceres, M., Rigoutsos, I., Bentwich, Z., and Lieberman, J. (2009). miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 114,2181-2192.
58. Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz, L. A., Jr., Hartigan, J., Smith, D. R., Strausberg, R. L., Marie, S. K., Shinjo, S. M., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., and Kinzler, K. W. (2008). An integrated genomic analysis of human glioblas-toma multiforme. Science 321, 1807-1812.
59. Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., and Maitra, A. (2011). Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 10, 1470-1480.
60. Qiu, X., Friedman, J. M., and Liang, G. (2011). Creating a flexible multiple microRNA expression vector by linking precursor microRNAs. Biochem. Biophys. Res. Commun. 411, 276-280.
61. Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., and Oren, M. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26,731-743.
62. Reya, T., Morrison, S. J., Clarke, M. E, and Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
63. Selbach, M., Schwanhausser, B., Thier-felder, N., Fang, Z., Khanin, R., and Rajewsky, N. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58-63.
64. Shen, Z., Zhan, G., Ye, D., Ren, Y., Cheng, L., Wu, Z., and Guo, J. (2012). MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the anti-apoptotic gene survivin. Med. Oncol. doi: 10.1007/s12032-011-0156-x.
65. Silber, J., Jacobsen, A., Ozawa, T., Harinath, G., Pedraza, A., Sander, C., Holland, E. C., and Huse, J. T. (2012). miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 7, e33844. doi: 10.1371/journal.pone.0033844
66. Sui, G., Affar el, B., Shi, Y., Brignone, C., Wall, N. R., Yin, P., Donohoe, M., Luke, M. P., Calvo, D., Grossman, S. R., and Shi, Y. (2004). Yin Yang 1 is a negative regulator of p53. Cell 117, 859-872.
67. Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., Sun, Z., and Zheng, X. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 582, 1564-1568.
68. Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., and Hermeking, H. (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6, 1586-1593.
69. Tazawa, H., Tsuchiya, N., Izumiya, M., and Nakagama, H. (2007). Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 104, 15472-15477.
70. Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., and Slack, E J. (2011). Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19,1116-1122.
71. Tryndyak, V. P., Ross, S. A., Beland, E A., and Pogribny, I. P. (2009). Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocar-cinogenesis induced by a methyl-deficient diet. Mol. Carcinog. 48, 479-487.
72. Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szasz, A. M., Wang, Z. C., Brock, J. E., Richardson, A. L., and Weinberg, R. A. (2009). A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046.
73. Vinall, R. L., Ripoll, A. Z., Wang, S., Pan, C. X., and Devere White, R. W. (2011). MiR-34a chemosen-sitizes bladder cancer cells to cis-platin treatment regardless of p53-Rb pathway status. Int. J. Cancer 130, 2526-2538.
74. Vogt, M., Munding, J., Gruner, M., Liffers, S. T., Verdoodt, B., Hauk, J., Steinstraesser, L., Tannapfel, A., and Hermeking, H. (2011). Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458, 313-322.
75. Wang, X., Wang, H. K., McCoy, J. P., Banerjee, N. S., Rader, J. S., Broker, T. R., Meyers, C., Chow, L. T., and Zheng, Z. M. (2009). Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15,637-647.
76. Weeraratne, S. D., Amani, V., Neiss, A., Teider, N., Scott, D. K., Pomeroy, S. L., and Cho, Y. J. (2010). miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 13, 165-175.
77. Wei, J. S., Song, Y K., Durinck, S., Chen, Q. R., Cheuk, A. T., Tsang, P., Zhang, Q., Thiele, C. J., Slack, A., Shohet, J., and Khan, J. (2008). The MYCN oncogene is a direct target of miR-34a. Oncogene 27, 5204-5213.
78. Welch, C., Chen, Y., and Stallings, R. L. (2007). MicroRNA-34afunctions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26, 5017-5022.
79. Welch, S. A. and Moore, M. J. (2007). Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncol. 3,247-254.
80. Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., and Bader, A. G. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70, 5923-5930.
81. Yamakuchi, M., Ferlito, M., and Lowenstein, C. J. (2008). miR-34arepression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13421-13426.
82. Yan, D., Zhou, X., Chen, X., Hu, D. N., Dong, X. D., Wang, J., Lu, F., Tu, L., and Qu, J. (2009). MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through down-regulation of c-Met. Invest. Ophthalmol. Vis. Sci. 50,1559-1565.
83. Yan, K., Gao, J., Yang, T., Ma, Q., Qiu, X., Fan, Q., and Ma, B. (2012). MicroRNA-34a inhibits the proliferation and metastasis of osteosar-coma cells both in vitro and in vivo. PLoS ONE 7, e33778. doi: 10.1371/ journal.pone.0033778